**Табела. 9.8** Компетентност ментора

|  |  |
| --- | --- |
| **Име и презиме** | [Лазар Поповић](http://kobson.nb.rs/nauka_u_srbiji.132.html?autor=Popovic%20Lazar%20S&amp;samoar&amp;.WYQaAbaxWUk) |
| **Звање** | Ванредни професор |
| **Ужа научна, уметничка односно стручна област** | Онкологија |
| **Академска каријера** | Година  | Институција  | Ужа научна, уметничка односно стручна област  |
| Избор у звање | 2020. | Медицински факултет Нови Сад | Онкологија |
| Докторат | 2014. | Медицински факултет Нови Сад | Онкологија |
| Специјализација | 2011. | Медицински факултет Нови Сад | Интерна медицина |
| Диплома | 2005. | Медицински факултет Нови Сад | Општа медицина |
| **Списак дисертација-докторских уметничких пројеката а у којима је наставнк ментор или је био ментор у претходних 10 година** |
| Р.Б. | Наслов дисертације- докторског уметничког пројекта  | Име кандидата | \*пријављена  | \*\* одбрањена |
| 1. | КЛИНИЧКА ВРЕДНОСТ ОДРЕЂИВАЊА Ки-67 ПРОЛИФЕРАТИВНОГ ИНДЕКСА У КАРЦИНОМИМА ДОЈКЕ СА ПОЗИТИВНИМ ХОРМОНСКИМ РЕЦЕПТОРИМА | Тања Лакић |  | 2018. |
| \*Година у којој је дисертација-докторски уметнички пројекат пријављена-пријављен (само за дисертације-докторске уметничке пројекте које су у току), \*\* Година у којој је дисертација-докторски уметнички пројекат одбрањена (само за дисертације-докторско уметничке пројекте из ранијег периода) |
| **Категоризација публикације научних радова из области датог студијског програма према класификацији ресорног Министарства просвете, науке и технолошког развоја а у складу са допунским захтевевима стандарда за дато поље**  |
| Р.б. | Публикација | ISI | M | IF |
| 1. | Cvetanovic A, Lambertini M, Punie K, Matovina-Brko G, Zivkovic N, Popovic M, Milovic-Kovacevic M, **Popovic L.** [Pharmacological methods for ovarian function and fertility preservation in women with cancer: A literature review.](https://pubmed.ncbi.nlm.nih.gov/39055889/) Oncol Res. 2024 Jul 17;32(8):1309-22. | 192/242(2023) | 23(2023) | 2.0(2023) |
| 2. | Rizzo M, ..., **Popovic L**, et al. [Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study.](https://www.nature.com/articles/s41598-024-70182-3) Sci Rep. 2024;14(1):19802. |  21/72  (2023) | 21(2023) | 3.8(2023) |
| 3. | Popovic Dj, Patoulias D, **Popovic L**, Karakasis P, Papanas N, Mantzoros C. [Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.](https://pubmed.ncbi.nlm.nih.gov/38925294/) Diabetes Res Clin Pract. 2024;213:111758. | 21/143(2023) | 21 (2023) | 6.1(2023) |
| 4. | Sabale U, Karamousouli E, **Popovic L,** Krasznai ZT, Harrop D, Meiwald A, Hughes R, Weston G, Bencina G. [The indirect costs of human papillomavirus-related cancer in Central and Eastern Europe: years of life lost and productivity costs.](https://pubmed.ncbi.nlm.nih.gov/38638098/) J Med Econ. 2024;27(sup2):1-8. | 45/108(2023) | 22(2023) | 2.9(2023) |
| 5. | Massari F, ..., **Popovic L**, et al. [Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.](https://pubmed.ncbi.nlm.nih.gov/38634928/) Cancer Immunol Immunother. 2024;73(6):106. | 72/242(2023) | 21(2023) | 4.6(2023) |
| 6. | Fiala O, ..., **Popovic L,** et al. [Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study](https://pubmed.ncbi.nlm.nih.gov/37676282/). Cancer Immunol Immunother. 2023;72(11):3665-3682. | 72/242 | 21 | 4.6 |
| 7. | van Halteren HK, Bennouna J, Brasiuniene B, Tomas AJC, Trinidad AMG, Indini A, Liposits G, Pellegrino B, **Popovic L**, Tan A, Vidra R, Strijbos M; Practising Oncologists Working Group. [Twelve ESMO Congress 2022 breakthroughs: practicing oncologists' perceptions and potential application on presented data](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843205/pdf/main.pdf). ESMO Open. 2023 Feb;8(1):100773. | 38/242 | 21 | 7.1 |
| 8. | **Popovic LS**, Matovina-Brko G, Popovic M, Punie K, Cvetanovic A, Lambertini M. [Targeting triple-negative breast cancer: A clinical perspective](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229315/pdf/OncolRes-31-28525.pdf). Oncol Res. 2023 May 24;31(3):221-38. | 94/245 (2021) | 22 (2021) | 4.938 (2021) |
| 9. | Santoni M, Myint ZW, Büttner T, ..., **Popovic L**, et al. [Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study](https://link.springer.com/article/10.1007/s00262-023-03469-5). Cancer Immunol Immunother. 2023 Sep;72(9):2961-70. | 72/242  | 21  | 4.6 |
| 10. | Pejčić T, Zeković M, Bumbaširević U, Kalaba M, Vovk I, Bensa M, **Popović L**, Tešić Ž. [The Role of Isoflavones in the Prevention of Breast Cancer and Prostate Cancer](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9952119/pdf/antioxidants-12-00368.pdf). Antioxidants (Basel). 2023 Feb 3;12(2):368. | 6/60 (2022) | 21a (2022) | 7.0 (2022) |
| 11. | Bencina G, Chami N, Hughes R, Weston G, Baxter C, Maciejczyk A, **Popovic L**, Karamousouli E, Salomonsson S. [Breast cancer-related mortality in Central and Eastern Europe: years of life lost and productivity costs](https://www.tandfonline.com/doi/epdf/10.1080/13696998.2023.2169497?needAccess=true&role=button). J Med Econ. 2023 Jan-Dec;26(1):254-61. | 45/108 | 22  | 2.9 |
| 12. | Pejčić T, Todorović Z, Đurašević S, **Popović L**. [Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917912/pdf/ijms-24-02939.pdf). Int J Mol Sci. 2023 Feb 2;24(3):2939. | 63/285 | 21  | 4.9 |
| 13. | Nikolić I, Radić J, Petreš A, Djurić A, Protić M, Litavski J, Popović M, Kolarov-Bjelobrk I, Dragin S, **Popović L**. [The Clinical Benefit of Percutaneous Transhepatic Biliary Drainage for Malignant Biliary Tract Obstruction](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563508/pdf/cancers-14-04673.pdf). Cancers (Basel). 2022 Sep 26;14(19):4673. | 72/242 | 21 | 5.2 |
| 14. | Mauri D, Kamposioras K, Matthaios D, ..., **Popovic L**, et al. Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy: Time to Rethink Our Approach. Oncol Res Treat. 2022;45(4):216-21. | 189/242 | 23 | 2.4 |
| 15. | Agostinetto E, Losurdo A, Nader-Marta G, Santoro A, Punie K, Barroso R, **Popovic L**, et al. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. Expert Opin Investig Drugs. 2022 Jun;31(6):567-91.  | 35/277 | 21 | 6.1 |
| 16. | Krivokuca A, Mihajlovic M, Susnjar S, Spasojevic IB, Minic I, **Popovic L**, Brankovic-Magic M. [Mutational profile of hereditary breast and ovarian cancer - Establishing genetic testing guidelines in a developing country](https://pdf.sciencedirectassets.com/272872/1-s2.0-S0147027221X00074/1-s2.0-S0147027221000842/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEG8aCXVzLWVhc3QtMSJHMEUCIQDmfcVU73WL1Jnc2fAiM4g6OIE%2BsuHnhvMoCMCVzvZ8nQIgTCFCVVyugUcqtDTFu%2BNozETXhcr5pfAz1%2F8o7CZ). Curr Probl Cancer. 2022 Feb;46(1):100767. | 176/242 | 23 | 2.6 |
| 17. | Tan AR, Wright GS, Thummala AR, Danso MA, **Popovic L**, Pluard TJ, et al. [Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377748/pdf/629.pdf). Clin Cancer Res. 2022 Feb 15;28(4):629-36. | 22/242 | 21a | 11.5 |
| 18. | **Popovic LS**, Matovina-Brko G, Popovic M, Popovic M, Cvetanovic A, Nikolic I, Kukic B, Petrovic D. [Immunotherapy in the treatment of lymphoma](https://www.wjgnet.com/1948-0210/full/v13/i6/503.htm). World J Stem Cells. 2021 Jun 26;13(6):503-20.  | 86/194 | 22 | 5.247 |
| 19. | Saif MW, Becerra CR, Fakih MG, Sun W, **Popovic L**, ..., Zaric B, et al. A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment. Cancer Chemother Pharmacol. 2021 Sep;88(3):485-97. | 137/279 | 22 | 3.581 |
| 20. | Kamposioras K, Mauri D, Papadimitriou K, Anthoney A, Hindi N, Petricevic B, Dambrosio M, Valachis A, Kountourakis P, Kopecky J, Kuhar CG, **Popovic L**, et al. [Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711151/pdf/fonc-10-575148.pdf). Front Oncol. 2020 Nov 19;10:575148. | 62/243 | 21 | 6.244 |
| 21. | Belkacemi Y, Grellier N, Ghith S, ...Tesanovic D,... **Popovic L**, et al. [A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries](https://www.sciencedirect.com/science/article/pii/S0959804920302811?via%3Dihub). Eur J Cancer. 2020 Aug;135:130-46. doi: 10.1016/j.ejca.2020.05.015. | 31/246 | 21 | 10.002 |
| 22. | Ivkovic [Kapicl T](http://ezproxy.nb.rs:2241/OutboundService.do?SID=D5fZj2WWCzOKdmCdd4a&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=3718041" \o "Find more records by this author), [Vicko F](http://ezproxy.nb.rs:2241/OutboundService.do?SID=D5fZj2WWCzOKdmCdd4a&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=4121960), [**Popovic L**](http://ezproxy.nb.rs:2241/OutboundService.do?SID=D5fZj2WWCzOKdmCdd4a&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=1386197), [Djilas D](http://ezproxy.nb.rs:2241/OutboundService.do?SID=D5fZj2WWCzOKdmCdd4a&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=5200014), [Lakic T](http://ezproxy.nb.rs:2241/OutboundService.do?SID=D5fZj2WWCzOKdmCdd4a&mode=rrcAuthorRecordService&action=go&product=WOS&lang=en_US&daisIds=35096638).[Secretory breast carcinoma in adulthood - A case report with literature review](http://www.doiserbia.nb.rs/img/doi/0042-8450/2020/0042-84501900143I.pdf). Vojnosanit Pregl. 2020;77(5):556-9. | 165/169 | 23 | 0.168 |
| 23. | Todorovic V, Aapro M, Pavlidis N, ..., Eri Z, ..., Knezevic Usaj S, ..., **Popovic L**, ..., Secen N, ..., Tesanovic D, ..., Vicko F, ..., Zaric B, et al. [AROME-ESO Oncology Consensus Conference: access to cancer care innovations in countries with limited resources. Association of Radiotherapy and Oncology of the Mediterranean Area (AROME-Paris) and European School of Oncology (ESO - Milan)](https://www.jbuon.com/archive/24-5-2180.pdf). J BUON. 2019 Sep-Oct;24(5):2180-97. | 221/244 | 23 | 1.695 |
| 24. | Tan AR, Wright GS, Thummala AR, Danso MA, **Popovic L**, Pluard TJ, et al. [Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial](https://pdf.sciencedirectassets.com/272203/1-s2.0-S1470204519X0011X/1-s2.0-S1470204519306163/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEG4aCXVzLWVhc3QtMSJHMEUCIQCHkOCxnIy4xxcYiQJjBKGtPZ2nIJtShi%2FbRRUreXJJ7wIgPbHQWKSt7Hj97H62z1Sal7fIjvh%2B1CeQsAJ0zzdrK). Lancet Oncol. 2019 Nov;20(11):1587-1601.  | 4/244 | 21a | 33.752 |
| 25. | Cvetanovic A, Pejcic I, Zivkovic N, Krtinic D, Kostic M, **Popovic L**. [Do we really know how to overcome trastuzumab resistance in hormone sensitive metastatic breast cancer?](https://www.jbuon.com/archive/24-2-516.pdf) J BUON. 2019 Mar-Apr;24(2):516-21. | 221/244 | 23 | 1.695 |
| 26. | **Popovic L**, Tomasevic Z, Stamatovic L, Markovic I, Matovina-Brko G, Buta M, Golubovic A, Selakovic V, Trifunovic J, Mutrezani Z, Ivanovic N, Nedovic J, Ninkovic S, Filipovic S, Cvetanovic A, Djordjevic N, Karanikolic A, Ivkovic-Kapic T, Vicko F. [Serbian consensus of neoadjuvant therapy for breast cancer: NeoPULSE](https://www.jbuon.com/archive/23-2-522.pdf). J BUON. 2018 Mar-Apr;23(2):522-32. | 215/230 | 23 | 1.379 |
| 27. | Cvetanovic A, Filipovic S, Zivkovic N, **Popovic L**, Kostic M, Djordjevic M, Karanikolic A, Krtinic D. [Ten years of using adjuvant trastuzumab in breast cancer in Serbia - Single institution experience](https://www.jbuon.com/archive/23-2-353.pdf). J BUON. 2018 Mar-Apr;23(2):353-60. | 215/230 | 23 | 1.379 |
| 28. | Popovic S, Jovanovic D, Mihaljevic B, Andjelkovic N, Marjanovic G, Marisavljevic D, Vlaisavljevic N, **Popovic L**, Salma S, Agic D, Milosevic R, Smiljanic M, Sretenović S, Djurdjević P, Markovic O, Hajder J, Govedarovic N. [Rituximab in the therapy of stage III and IV follicular lymphoma: Results of the REFLECT 1 study of the Serbian Lymphoma Group](https://www.jbuon.com/archive/22-2-487.pdf). J BUON. 2017 Mar-Apr;22(2):487-94. | 189/223 | 23 | 1.766 |
| 29. | **Popovic L**, Popovic M. [Editorial comment to Clinical analysis of severe psychiatric disorders in patients with testicular cancer: a single-center experience](https://ezproxy.nb.rs:2069/doi/epdf/10.1111/iju.13113). Int J Urol.  2016;23(7):628. | 41/77 | 22 | 1.884 |
| 30. | Popović DS, **Popović LS**. [Obesity and breast cancer - association even more relevant in males](http://ac.els-cdn.com/S0953620515004215/1-s2.0-S0953620515004215-main.pdf?_tid=785e12d6-78e3-11e7-9eb6-00000aab0f6c&acdnat=1501830600_4c2c2d1d5efde2386c90cda1188ae1af)? Eur J Intern Med. 2016;29:e11–2. (Letter) | 28/154 | 25 | 2.960 |
| 31. | Cvetanović A, **Popović L**, Filipović S, Trifunović J, Živković N, Matovina-Brko Gorana, Kostić M, Vicko F, Kocić B, Kolarov-Bjelobrk I. [Young age and pathological features predict breast cancer outcome - report from dual institution experience in Serbia](https://www.jbuon.com/pdfs/20-6-3.pdf). J BUON. 2015;20(6):1407-13. | 202/213 | 23 | 0.880 |
| 32. | Markovic O, **Popovic L**, Marisavljevic D, Jovanovic D, Filipovic B, Stanisavljevic D, Matovina-Brko G, Hajder J, et al. [Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma](http://ac.els-cdn.com/S0953620514000430/1-s2.0-S0953620514000430-main.pdf?_tid=45f274ca-19e0-11e7-8be3-00000aab0f02&acdnat=1491383849_41f9d8c92173175c92966f57aa52da54). Eur J Intern Med. 2014;25(3):296-302. | 26/154 | 21 | 2.891 |
| 33. | **Popović L**, Trifunovic J, Pesic J, Matovina-Brko G, Kolarov-Bjelobrk I, Memisevic N, Jovanovic D. [Male breast cancer in the era of modern therapies: Serbian single centre experience report](http://onlinelibrary.wiley.com/doi/10.1111/tbj.12268/pdf). Breast J. 2014;20(3):329-30. (Letter) | 37/78(2012) | 25(2012) | 1.831(2012) |
| 34. | **Popović L**, Jovanović D, Petrović D, Nikin Z, Matovina-Brko G, Trifunovic J, Kolarov-Bjelobrk I. [Concurrent chronic lymphocytic leukemia and Merkel cell carcinoma in primary skin tumor and metastatic lymph node: a case report](http://download.springer.com/static/pdf/874/art%253A10.1007%252Fs12288-014-0447-4.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12288-014-0447-4&token2=exp=1497335167~acl=%2Fstatic%2Fpdf%2F874%2Fart%25253A10.1007%25252Fs12288-014-0447). Indian j Hematol Blood Transf. 2014;30(Suppl 1):S422-4. | 67/68 | 23 | 0.198 |
| 35. | Matovina-Brko G, Ruzic M, Fabri M, **Popovic L**, Kolarov-Bjelobrk I, Trifunovic J, Petkovic D. [Treatment of acute hepatitis C in breast cancer patient: a case report.](https://pubmed.ncbi.nlm.nih.gov/24621156/) J Chemother. 2014;26(3):180-3. | 175/255 | 23 | 1.604 |
| **Збирни подаци научне активност наставника** |
| Укупан број цитата, без аутоцитата | 389 |
| Укупан број радова са SCI (или SSCI) листе | 40 |
| Тренутно учешће на пројектима | Домаћи: 1 | Међународни: - |
| Усавршавања |  |
| Други подаци које сматрате релевантним |  |